RARA and acute myeloid leukemia: While translocation-driven leukemias (e.g., PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11) can be tested by qPCR with high sensitivity similar to AMLs with NPM1 mutations, for most AML patients molecular-based MRD is not an option due to the lack of a robustly targetable mutation to measure.